Last reviewed · How we verify
iseganan HCl oral solution
iseganan HCl oral solution is a Small molecule drug developed by National Cancer Institute (NCI). It is currently in Phase 3 development.
At a glance
| Generic name | iseganan HCl oral solution |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer (PHASE3)
- Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iseganan HCl oral solution CI brief — competitive landscape report
- iseganan HCl oral solution updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI
Frequently asked questions about iseganan HCl oral solution
What is iseganan HCl oral solution?
iseganan HCl oral solution is a Small molecule drug developed by National Cancer Institute (NCI).
Who makes iseganan HCl oral solution?
iseganan HCl oral solution is developed by National Cancer Institute (NCI) (see full National Cancer Institute (NCI) pipeline at /company/national-cancer-institute-nci).
What development phase is iseganan HCl oral solution in?
iseganan HCl oral solution is in Phase 3.